CStone Pharmaceuticals (2616.HK) Stock Competitors & Peer Comparison
See (2616.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2616.HK | HK$4.79 | +2.35% | 7.6B | -19.27 | -HK$0.25 | N/A |
| 4332.HK | HK$1,850.00 | +0.00% | 998.5B | 45.81 | HK$40.38 | N/A |
| 6160.HK | HK$194.60 | +0.83% | 265B | 88.84 | HK$2.21 | N/A |
| 2269.HK | HK$39.22 | +1.03% | 160.9B | 30.39 | HK$1.28 | N/A |
| 1801.HK | HK$91.65 | -0.54% | 160.6B | 169.64 | HK$0.54 | N/A |
| 6990.HK | HK$525.00 | +2.64% | 120.6B | -256.32 | -HK$2.02 | N/A |
| 9926.HK | HK$104.90 | +10.89% | 91B | -73.72 | -HK$1.34 | N/A |
| 3347.HK | HK$38.00 | +1.23% | 46.3B | 39.06 | HK$0.98 | +0.38% |
| 1530.HK | HK$17.64 | +4.26% | 43.2B | 4.50 | HK$3.84 | +1.45% |
| 6821.HK | HK$119.20 | -2.61% | 42.9B | 38.98 | HK$3.05 | +1.26% |
Stock Comparison
2616.HK vs 4332.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 4332.HK trades at HK$1,850.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 4332.HK's competition here
2616.HK vs 6160.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6160.HK has a market cap of 265B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6160.HK trades at HK$194.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6160.HK's P/E ratio is 88.84. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 2616.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6160.HK's competition here
2616.HK vs 2269.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2269.HK has a market cap of 160.9B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2269.HK trades at HK$39.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2269.HK's P/E ratio is 30.39. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2269.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2269.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2269.HK's competition here
2616.HK vs 1801.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1801.HK has a market cap of 160.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1801.HK trades at HK$91.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1801.HK's P/E ratio is 169.64. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1801.HK's ROE of +0.05%. Regarding short-term risk, 2616.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1801.HK's competition here
2616.HK vs 6990.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6990.HK has a market cap of 120.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6990.HK trades at HK$525.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6990.HK's P/E ratio is -256.32. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6990.HK's ROE of -0.10%. Regarding short-term risk, 2616.HK is more volatile compared to 6990.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6990.HK's competition here
2616.HK vs 9926.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9926.HK has a market cap of 91B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9926.HK trades at HK$104.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9926.HK's P/E ratio is -73.72. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9926.HK's ROE of -0.14%. Regarding short-term risk, 2616.HK is less volatile compared to 9926.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 9926.HK's competition here
2616.HK vs 3347.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 3347.HK has a market cap of 46.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 3347.HK trades at HK$38.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 3347.HK's P/E ratio is 39.06. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3347.HK's ROE of +0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 3347.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3347.HK's competition here
2616.HK vs 1530.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1530.HK has a market cap of 43.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1530.HK trades at HK$17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1530.HK's P/E ratio is 4.50. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1530.HK's ROE of +0.39%. Regarding short-term risk, 2616.HK is more volatile compared to 1530.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1530.HK's competition here
2616.HK vs 6821.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6821.HK has a market cap of 42.9B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6821.HK trades at HK$119.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6821.HK's P/E ratio is 38.98. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6821.HK's ROE of +0.06%. Regarding short-term risk, 2616.HK is less volatile compared to 6821.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6821.HK's competition here
2616.HK vs 2096.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2096.HK has a market cap of 34.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2096.HK trades at HK$13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2096.HK's P/E ratio is 22.48. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2096.HK's ROE of +0.16%. Regarding short-term risk, 2616.HK is more volatile compared to 2096.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2096.HK's competition here
2616.HK vs 1548.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1548.HK has a market cap of 34.1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1548.HK trades at HK$16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1548.HK's P/E ratio is -47.88. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1548.HK's ROE of -0.13%. Regarding short-term risk, 2616.HK is less volatile compared to 1548.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1548.HK's competition here
2616.HK vs 2696.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2696.HK has a market cap of 31.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2696.HK trades at HK$58.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2696.HK's P/E ratio is 23.42. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2696.HK's ROE of +0.22%. Regarding short-term risk, 2616.HK is more volatile compared to 2696.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2696.HK's competition here
2616.HK vs 1877.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1877.HK has a market cap of 27.1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1877.HK trades at HK$19.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1877.HK's P/E ratio is -28.34. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1877.HK's ROE of -0.11%. Regarding short-term risk, 2616.HK is less volatile compared to 1877.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1877.HK's competition here
2616.HK vs 2162.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2162.HK has a market cap of 24.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2162.HK trades at HK$86.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2162.HK's P/E ratio is -39.57. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2162.HK's ROE of -0.17%. Regarding short-term risk, 2616.HK is less volatile compared to 2162.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2162.HK's competition here
2616.HK vs 9606.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9606.HK has a market cap of 21.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9606.HK trades at HK$237.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9606.HK's P/E ratio is -35.63. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9606.HK's ROE of -0.97%. Regarding short-term risk, 2616.HK is less volatile compared to 9606.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 9606.HK's competition here
2616.HK vs 9969.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9969.HK has a market cap of 21.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9969.HK trades at HK$14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9969.HK's P/E ratio is 32.33. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9969.HK's ROE of +0.10%. Regarding short-term risk, 2616.HK is less volatile compared to 9969.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 9969.HK's competition here
2616.HK vs 2315.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2315.HK has a market cap of 21B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2315.HK trades at HK$53.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2315.HK's P/E ratio is 142.00. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2315.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is less volatile compared to 2315.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2315.HK's competition here
2616.HK vs 9688.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9688.HK has a market cap of 18.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9688.HK trades at HK$15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9688.HK's P/E ratio is -12.73. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9688.HK's ROE of -0.24%. Regarding short-term risk, 2616.HK is more volatile compared to 9688.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9688.HK's competition here
2616.HK vs 6855.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6855.HK has a market cap of 14B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6855.HK trades at HK$37.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6855.HK's P/E ratio is -11.97. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6855.HK's ROE of -1.24%. Regarding short-term risk, 2616.HK is more volatile compared to 6855.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6855.HK's competition here
2616.HK vs 9887.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9887.HK has a market cap of 13.1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9887.HK trades at HK$66.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9887.HK's P/E ratio is -508.08. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9887.HK's ROE of -0.10%. Regarding short-term risk, 2616.HK is less volatile compared to 9887.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 9887.HK's competition here
2616.HK vs 2493.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2493.HK has a market cap of 12.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2493.HK trades at HK$23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2493.HK's P/E ratio is -8.55. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2493.HK's ROE of -1.81%. Regarding short-term risk, 2616.HK is more volatile compared to 2493.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2493.HK's competition here
2616.HK vs 7666.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 7666.HK has a market cap of 12.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 7666.HK trades at HK$12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 7666.HK's P/E ratio is -27.36. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 7666.HK's ROE of +2.70%. Regarding short-term risk, 2616.HK is less volatile compared to 7666.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 7666.HK's competition here
2616.HK vs 2595.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2595.HK has a market cap of 12.4B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2595.HK trades at HK$36.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2595.HK's P/E ratio is -5.23. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2595.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 2595.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2595.HK's competition here
2616.HK vs 2142.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2142.HK has a market cap of 10.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2142.HK trades at HK$12.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2142.HK's P/E ratio is 214.18. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2142.HK's ROE of +0.17%. Regarding short-term risk, 2616.HK is more volatile compared to 2142.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2142.HK's competition here
2616.HK vs 2627.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2627.HK has a market cap of 10.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2627.HK trades at HK$29.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2627.HK's P/E ratio is -44.42. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2627.HK's ROE of -2.54%. Regarding short-term risk, 2616.HK is less volatile compared to 2627.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2627.HK's competition here
2616.HK vs 2335.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2335.HK has a market cap of 9.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2335.HK trades at HK$34.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2335.HK's P/E ratio is -57.43. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2335.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 2335.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2335.HK's competition here
2616.HK vs 6938.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6938.HK has a market cap of 9.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6938.HK trades at HK$54.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6938.HK's P/E ratio is -27.11. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6938.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 6938.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6938.HK's competition here
2616.HK vs 1672.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1672.HK has a market cap of 9.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1672.HK trades at HK$8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1672.HK's P/E ratio is -21.21. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1672.HK's ROE of -0.19%. Regarding short-term risk, 2616.HK is less volatile compared to 1672.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1672.HK's competition here
2616.HK vs 1952.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1952.HK has a market cap of 9B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1952.HK trades at HK$25.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1952.HK's P/E ratio is -5.79. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1952.HK's ROE of -0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 1952.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1952.HK's competition here
2616.HK vs 6872.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6872.HK has a market cap of 8.9B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6872.HK trades at HK$172.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6872.HK's P/E ratio is -49.48. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6872.HK's ROE of +0.41%. Regarding short-term risk, 2616.HK is less volatile compared to 6872.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6872.HK's competition here
2616.HK vs 2157.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2157.HK has a market cap of 8.8B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2157.HK trades at HK$4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2157.HK's P/E ratio is -44.41. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2157.HK's ROE of +0.24%. Regarding short-term risk, 2616.HK is less volatile compared to 2157.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2157.HK's competition here
2616.HK vs 2171.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2171.HK has a market cap of 8.5B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2171.HK trades at HK$14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2171.HK's P/E ratio is -75.73. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2171.HK's ROE of -0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2171.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2171.HK's competition here
2616.HK vs 6185.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6185.HK has a market cap of 8.5B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6185.HK trades at HK$24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6185.HK's P/E ratio is -3284.75. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6185.HK's ROE of -0.00%. Regarding short-term risk, 2616.HK is more volatile compared to 6185.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6185.HK's competition here
2616.HK vs 2256.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2256.HK has a market cap of 7.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2256.HK trades at HK$10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2256.HK's P/E ratio is -46.31. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2256.HK's ROE of +0.03%. Regarding short-term risk, 2616.HK is more volatile compared to 2256.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2256.HK's competition here
2616.HK vs 9966.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9966.HK has a market cap of 7.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9966.HK trades at HK$7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9966.HK's P/E ratio is 30.63. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9966.HK's ROE of -0.06%. Regarding short-term risk, 2616.HK is less volatile compared to 9966.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 9966.HK's competition here
2616.HK vs 6826.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6826.HK has a market cap of 6.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6826.HK trades at HK$16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6826.HK's P/E ratio is 22.37. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6826.HK's ROE of +0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 6826.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6826.HK's competition here
2616.HK vs 1779.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1779.HK has a market cap of 6.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1779.HK trades at HK$93.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1779.HK's P/E ratio is -33.21. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1779.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 1779.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1779.HK's competition here
2616.HK vs 1477.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1477.HK has a market cap of 4.8B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1477.HK trades at HK$5.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1477.HK's P/E ratio is -25.78. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1477.HK's ROE of -0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 1477.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1477.HK's competition here
2616.HK vs 2617.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2617.HK has a market cap of 4.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2617.HK trades at HK$10.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2617.HK's P/E ratio is -12.39. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2617.HK's ROE of -0.74%. Regarding short-term risk, 2616.HK is more volatile compared to 2617.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2617.HK's competition here
2616.HK vs 1167.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1167.HK has a market cap of 4.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1167.HK trades at HK$5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1167.HK's P/E ratio is -51.41. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1167.HK's ROE of -0.18%. Regarding short-term risk, 2616.HK is more volatile compared to 1167.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1167.HK's competition here
2616.HK vs 2591.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2591.HK has a market cap of 3.8B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2591.HK trades at HK$8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2591.HK's P/E ratio is -9.07. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2591.HK's ROE of -0.38%. Regarding short-term risk, 2616.HK is less volatile compared to 2591.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2591.HK's competition here
2616.HK vs 2629.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2629.HK has a market cap of 3.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2629.HK trades at HK$12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2629.HK's P/E ratio is -4.53. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2629.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 2629.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2629.HK's competition here
2616.HK vs 6132.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6132.HK has a market cap of 3.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6132.HK trades at HK$47.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6132.HK's P/E ratio is -20.07. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6132.HK's ROE of -0.43%. Regarding short-term risk, 2616.HK is less volatile compared to 6132.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6132.HK's competition here
2616.HK vs 3378.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 3378.HK has a market cap of 3.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 3378.HK trades at HK$26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 3378.HK's P/E ratio is 114.13. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3378.HK's ROE of +0.13%. Regarding short-term risk, 2616.HK is more volatile compared to 3378.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3378.HK's competition here
2616.HK vs 2509.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2509.HK has a market cap of 3.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2509.HK trades at HK$16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2509.HK's P/E ratio is 9.71. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2509.HK's ROE of +0.68%. Regarding short-term risk, 2616.HK is more volatile compared to 2509.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2509.HK's competition here
2616.HK vs 3880.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 3880.HK has a market cap of 3.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 3880.HK trades at HK$23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 3880.HK's P/E ratio is 26.01. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3880.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 3880.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3880.HK's competition here
2616.HK vs 6955.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6955.HK has a market cap of 3.1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6955.HK trades at HK$4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6955.HK's P/E ratio is 500.00. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6955.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 6955.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6955.HK's competition here
2616.HK vs 2105.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2105.HK has a market cap of 3.1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2105.HK trades at HK$6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2105.HK's P/E ratio is -10.15. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2105.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 2105.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2105.HK's competition here
2616.HK vs 2659.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2659.HK has a market cap of 2.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2659.HK trades at HK$17.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2659.HK's P/E ratio is -11.15. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2659.HK's ROE of N/A. Regarding short-term risk, 2616.HK and 2659.HK have similar daily volatility (4.22).Check 2659.HK's competition here
2616.HK vs 1873.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1873.HK has a market cap of 2.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1873.HK trades at HK$1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1873.HK's P/E ratio is 20.32. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1873.HK's ROE of +0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 1873.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1873.HK's competition here
2616.HK vs 2179.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2179.HK has a market cap of 2.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2179.HK trades at HK$5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2179.HK's P/E ratio is -3.41. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2179.HK's ROE of -1.37%. Regarding short-term risk, 2616.HK is more volatile compared to 2179.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2179.HK's competition here
2616.HK vs 2480.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2480.HK has a market cap of 2.6B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2480.HK trades at HK$13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2480.HK's P/E ratio is -14.94. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2480.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 2480.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2480.HK's competition here
2616.HK vs 6996.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6996.HK has a market cap of 2.5B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6996.HK trades at HK$4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6996.HK's P/E ratio is -9.53. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6996.HK's ROE of -0.34%. Regarding short-term risk, 2616.HK is less volatile compared to 6996.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6996.HK's competition here
2616.HK vs 1875.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1875.HK has a market cap of 2.4B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1875.HK trades at HK$3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1875.HK's P/E ratio is 306.84. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1875.HK's ROE of -0.15%. Regarding short-term risk, 2616.HK is more volatile compared to 1875.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1875.HK's competition here
2616.HK vs 6681.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6681.HK has a market cap of 2.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6681.HK trades at HK$1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6681.HK's P/E ratio is -13.72. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6681.HK's ROE of -1.83%. Regarding short-term risk, 2616.HK is less volatile compared to 6681.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6681.HK's competition here
2616.HK vs 1521.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1521.HK has a market cap of 2.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1521.HK trades at HK$1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1521.HK's P/E ratio is 65.93. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1521.HK's ROE of +0.02%. Regarding short-term risk, 2616.HK is more volatile compared to 1521.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1521.HK's competition here
2616.HK vs 2197.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2197.HK has a market cap of 2.1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2197.HK trades at HK$1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2197.HK's P/E ratio is -2.08. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2197.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is less volatile compared to 2197.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2197.HK's competition here
2616.HK vs 2565.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2565.HK has a market cap of 2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2565.HK trades at HK$6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2565.HK's P/E ratio is -11.02. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2565.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 2565.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2565.HK's competition here
2616.HK vs 6660.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6660.HK has a market cap of 1.8B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6660.HK trades at HK$1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6660.HK's P/E ratio is -2.36. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6660.HK's ROE of -0.22%. Regarding short-term risk, 2616.HK is more volatile compared to 6660.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6660.HK's competition here
2616.HK vs 2181.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2181.HK has a market cap of 1.7B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2181.HK trades at HK$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2181.HK's P/E ratio is -12.33. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2181.HK's ROE of +0.44%. Regarding short-term risk, 2616.HK is more volatile compared to 2181.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2181.HK's competition here
2616.HK vs 6622.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6622.HK has a market cap of 1.4B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6622.HK trades at HK$2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6622.HK's P/E ratio is -4.78. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6622.HK's ROE of -0.13%. Regarding short-term risk, 2616.HK is more volatile compared to 6622.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6622.HK's competition here
2616.HK vs 1541.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1541.HK has a market cap of 1.4B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1541.HK trades at HK$3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1541.HK's P/E ratio is -4.10. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1541.HK's ROE of -0.33%. Regarding short-term risk, 2616.HK is more volatile compared to 1541.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1541.HK's competition here
2616.HK vs 2566.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2566.HK has a market cap of 1.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2566.HK trades at HK$5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2566.HK's P/E ratio is 8.54. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2566.HK's ROE of N/A. Regarding short-term risk, 2616.HK is less volatile compared to 2566.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2566.HK's competition here
2616.HK vs 3681.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 3681.HK has a market cap of 1.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 3681.HK trades at HK$1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 3681.HK's P/E ratio is -6.35. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3681.HK's ROE of -0.28%. Regarding short-term risk, 2616.HK is more volatile compared to 3681.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3681.HK's competition here
2616.HK vs 2511.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2511.HK has a market cap of 1.3B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2511.HK trades at HK$2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2511.HK's P/E ratio is -3.72. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2511.HK's ROE of -0.39%. Regarding short-term risk, 2616.HK is less volatile compared to 2511.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2511.HK's competition here
2616.HK vs 2592.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2592.HK has a market cap of 1.2B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2592.HK trades at HK$1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2592.HK's P/E ratio is -1.71. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2592.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 2592.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2592.HK's competition here
2616.HK vs 2898.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2898.HK has a market cap of 1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2898.HK trades at HK$6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2898.HK's P/E ratio is -10.49. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2898.HK's ROE of -0.39%. Regarding short-term risk, 2616.HK is more volatile compared to 2898.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2898.HK's competition here
2616.HK vs 6998.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6998.HK has a market cap of 1B. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6998.HK trades at HK$1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6998.HK's P/E ratio is -3.58. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6998.HK's ROE of +0.18%. Regarding short-term risk, 2616.HK is more volatile compared to 6998.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6998.HK's competition here
2616.HK vs 2487.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2487.HK has a market cap of 926.6M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2487.HK trades at HK$2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2487.HK's P/E ratio is -1.60. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2487.HK's ROE of -0.41%. Regarding short-term risk, 2616.HK is more volatile compared to 2487.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2487.HK's competition here
2616.HK vs 1228.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1228.HK has a market cap of 841.2M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1228.HK trades at HK$2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1228.HK's P/E ratio is -3.01. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1228.HK's ROE of -0.04%. Regarding short-term risk, 2616.HK is less volatile compared to 1228.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1228.HK's competition here
2616.HK vs 9939.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 9939.HK has a market cap of 801.8M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 9939.HK trades at HK$1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 9939.HK's P/E ratio is -4.21. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9939.HK's ROE of -0.99%. Regarding short-term risk, 2616.HK is more volatile compared to 9939.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9939.HK's competition here
2616.HK vs 2496.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2496.HK has a market cap of 740.7M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2496.HK trades at HK$3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2496.HK's P/E ratio is -7.24. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2496.HK's ROE of +2.42%. Regarding short-term risk, 2616.HK is more volatile compared to 2496.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2496.HK's competition here
2616.HK vs 2137.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2137.HK has a market cap of 721.2M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2137.HK trades at HK$0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2137.HK's P/E ratio is -3.18. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2137.HK's ROE of -0.09%. Regarding short-term risk, 2616.HK is less volatile compared to 2137.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2137.HK's competition here
2616.HK vs 2126.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2126.HK has a market cap of 699.7M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2126.HK trades at HK$1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2126.HK's P/E ratio is -1.10. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2126.HK's ROE of -0.75%. Regarding short-term risk, 2616.HK is less volatile compared to 2126.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2126.HK's competition here
2616.HK vs 2185.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2185.HK has a market cap of 577.5M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2185.HK trades at HK$2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2185.HK's P/E ratio is -3.94. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2185.HK's ROE of -0.15%. Regarding short-term risk, 2616.HK is more volatile compared to 2185.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2185.HK's competition here
2616.HK vs 1244.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 1244.HK has a market cap of 541M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 1244.HK trades at HK$2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 1244.HK's P/E ratio is -2.65. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1244.HK's ROE of -0.27%. Regarding short-term risk, 2616.HK is less volatile compared to 1244.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1244.HK's competition here
2616.HK vs 0690.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 0690.HK has a market cap of 501.6M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 0690.HK trades at HK$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 0690.HK's P/E ratio is 6.25. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 0690.HK's ROE of +0.23%. Regarding short-term risk, 2616.HK is more volatile compared to 0690.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 0690.HK's competition here
2616.HK vs 6628.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6628.HK has a market cap of 481.6M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6628.HK trades at HK$1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6628.HK's P/E ratio is -0.80. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6628.HK's ROE of -0.32%. Regarding short-term risk, 2616.HK is more volatile compared to 6628.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6628.HK's competition here
2616.HK vs 2257.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2257.HK has a market cap of 435.6M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2257.HK trades at HK$4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2257.HK's P/E ratio is -3.02. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2257.HK's ROE of +1.92%. Regarding short-term risk, 2616.HK is less volatile compared to 2257.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2257.HK's competition here
2616.HK vs 2396.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 2396.HK has a market cap of 323.8M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 2396.HK trades at HK$3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 2396.HK's P/E ratio is -1.62. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2396.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 2396.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2396.HK's competition here
2616.HK vs 6978.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 6978.HK has a market cap of 282.4M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 6978.HK trades at HK$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 6978.HK's P/E ratio is -1.42. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6978.HK's ROE of +2.93%. Regarding short-term risk, 2616.HK is more volatile compared to 6978.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6978.HK's competition here
2616.HK vs 8158.HK Comparison July 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 7.6B. In comparison, 8158.HK has a market cap of 82.1M. Regarding current trading prices, 2616.HK is priced at HK$4.79, while 8158.HK trades at HK$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -19.27, whereas 8158.HK's P/E ratio is -0.74. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 8158.HK's ROE of +0.67%. Regarding short-term risk, 2616.HK is more volatile compared to 8158.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 8158.HK's competition here